中国急救复苏与灾害医学杂志
中國急救複囌與災害醫學雜誌
중국급구복소여재해의학잡지
CHINA JOURNAL OF EMERGENCY RESUSCITATION AND DISASTER MEDICINE
2015年
7期
608-611
,共4页
任超%张才溢%丁红梅%陈浩%耿润露%刘小云%万美荣%耿德勤%许铁
任超%張纔溢%丁紅梅%陳浩%耿潤露%劉小雲%萬美榮%耿德勤%許鐵
임초%장재일%정홍매%진호%경윤로%류소운%만미영%경덕근%허철
间充质干细胞%神经干细胞%鞘内注射%神经变性疾病%干细胞移植
間充質榦細胞%神經榦細胞%鞘內註射%神經變性疾病%榦細胞移植
간충질간세포%신경간세포%초내주사%신경변성질병%간세포이식
Mesenchymal stem cells%Neural stem cells%Intrathecal injection%Neurodegenerative diseases%Stem cell transplantation
目的:探索腰椎穿刺鞘内注射移植间充质干细胞(MSCs)或经脑脊液诱导分化的神经样干细胞(NSCs)治疗神经变性疾病(NDD)的临床疗效和安全性。方法根据骨髓细胞学分析结果是否正常,将14例符合入选标准的NDD患者分为:骨髓源干细胞治疗组(A组,骨髓细胞正常),脐血源干细胞治疗组(B组)。采用分离培养、脑脊液诱导分化方法获得MSCs和NSCs,通过腰椎穿刺鞘内注射进行细胞移植治疗;于移植治疗前、首次移植后3个月、6个月,采用特定神经功能量表、生活活动能力量表(BI)及生活质量量表(EuroQOL)对患者神经功能状况进行评估;同期,观察记录移植相关不良反应及并发症。结果14例NDD患者中A组8例、B组6例,性别构成、平均年龄差异无统计学意义。细胞移植后A组和B组患者的神经功能有不同程度的改善;治疗后BI分值和EuroQOL分值优于治疗前,差异有统计学意义;而2组间差异无统计学意义。移植术后有3例出现过短暂性低热,A组2例,B组1例,对症处理可控制;随访期间A组有1例患者发生心源性猝死,B组有3例患者死于继发性肺部感染。最长随访时间已超过2年,未出现继发性肿瘤等细胞移植严重并发症。结论腰穿鞘内注射移植骨髓源或脐血源MSCs及其经脑脊液诱导获得的NSCs能显著改善NDD患者的神经功能,无严重不良发应和并发症;当NDD患者自身骨髓细胞分析异常,可用脐血源干细胞替代自体骨髓源干细胞进行细胞移植治疗。
目的:探索腰椎穿刺鞘內註射移植間充質榦細胞(MSCs)或經腦脊液誘導分化的神經樣榦細胞(NSCs)治療神經變性疾病(NDD)的臨床療效和安全性。方法根據骨髓細胞學分析結果是否正常,將14例符閤入選標準的NDD患者分為:骨髓源榦細胞治療組(A組,骨髓細胞正常),臍血源榦細胞治療組(B組)。採用分離培養、腦脊液誘導分化方法穫得MSCs和NSCs,通過腰椎穿刺鞘內註射進行細胞移植治療;于移植治療前、首次移植後3箇月、6箇月,採用特定神經功能量錶、生活活動能力量錶(BI)及生活質量量錶(EuroQOL)對患者神經功能狀況進行評估;同期,觀察記錄移植相關不良反應及併髮癥。結果14例NDD患者中A組8例、B組6例,性彆構成、平均年齡差異無統計學意義。細胞移植後A組和B組患者的神經功能有不同程度的改善;治療後BI分值和EuroQOL分值優于治療前,差異有統計學意義;而2組間差異無統計學意義。移植術後有3例齣現過短暫性低熱,A組2例,B組1例,對癥處理可控製;隨訪期間A組有1例患者髮生心源性猝死,B組有3例患者死于繼髮性肺部感染。最長隨訪時間已超過2年,未齣現繼髮性腫瘤等細胞移植嚴重併髮癥。結論腰穿鞘內註射移植骨髓源或臍血源MSCs及其經腦脊液誘導穫得的NSCs能顯著改善NDD患者的神經功能,無嚴重不良髮應和併髮癥;噹NDD患者自身骨髓細胞分析異常,可用臍血源榦細胞替代自體骨髓源榦細胞進行細胞移植治療。
목적:탐색요추천자초내주사이식간충질간세포(MSCs)혹경뇌척액유도분화적신경양간세포(NSCs)치료신경변성질병(NDD)적림상료효화안전성。방법근거골수세포학분석결과시부정상,장14례부합입선표준적NDD환자분위:골수원간세포치료조(A조,골수세포정상),제혈원간세포치료조(B조)。채용분리배양、뇌척액유도분화방법획득MSCs화NSCs,통과요추천자초내주사진행세포이식치료;우이식치료전、수차이식후3개월、6개월,채용특정신경공능량표、생활활동능역량표(BI)급생활질량량표(EuroQOL)대환자신경공능상황진행평고;동기,관찰기록이식상관불량반응급병발증。결과14례NDD환자중A조8례、B조6례,성별구성、평균년령차이무통계학의의。세포이식후A조화B조환자적신경공능유불동정도적개선;치료후BI분치화EuroQOL분치우우치료전,차이유통계학의의;이2조간차이무통계학의의。이식술후유3례출현과단잠성저열,A조2례,B조1례,대증처리가공제;수방기간A조유1례환자발생심원성졸사,B조유3례환자사우계발성폐부감염。최장수방시간이초과2년,미출현계발성종류등세포이식엄중병발증。결론요천초내주사이식골수원혹제혈원MSCs급기경뇌척액유도획득적NSCs능현저개선NDD환자적신경공능,무엄중불량발응화병발증;당NDD환자자신골수세포분석이상,가용제혈원간세포체대자체골수원간세포진행세포이식치료。
Objective To explore the clinical efficacy and safety of intrathecal transplantation of human mesenchymal stem cells (MSCs) or cerebrospinal fluid (CSF) induced neural stem cells (NSCs) by lumbar puncture to treat patients with neurodegenerative diseases (NDD). Methods A total of 14 eligible patients with NDD were divided into a bone marrow stem cell (MSC) treatment group (Group A, normal bone marrow cells) and a umbilical cord blood stem cell (NSC) treatment group (Group B, with abnormal bone marrow cytology), according to their cytological examination of the bone marrow. Then, MSCs and NSCs obtained through isolation and differentiation inducement by CSF were intrathecally injected by lumbar puncture for transplantation therapy. The neurological function of all patients were evaluated using a specific neurological scale, the life events scale (BI) and the quality of life scale (EuroQOL) before, three months and six months after transplantation. Meanwhile, adverse reactions and complications related transplantation were recorded. Results There were eight patients Group A and six in Group B, with no statistical difference in gender and average age. After cell transplantation, patients presented improved nervous functions in both Groups A and B. The scores of BI and EuroQOL were better than those prior to treatment. For adverse reactions, three patients reported a transient fever (2 cases in Group A and 1 case in Group B) which were controlled after symptomatic treatment. During follow-up visits, one patients in Group A died of sudden cardiac death, while three patients in Group B died due to secondary pulmonary infection. The longest follow-up period was more than 2 years, without secondary tumor and other serious complications. Conclusion Intrathecal injection of MSCs and CSF-induced NSCs by lumbar puncture can remarkably improve the neurological function of patients with NDD, without serious adverse reaction and complications. When NDD patients manifested abnormal bone marrow cytological results, umbilical cord blood stem cells can replace autologous bone marrow stem cells for transplantation therapy.